title: Policy change to improve pathology turnaround time and reduce costs--possible to do both?
abstract: BACKGROUND
  Overcrowding and prolonged length of stay in emergency departments (ED) are increasing problems in hospitals. Rapid availability of all laboratory results has an impact on clinical decision-making, admissions or discharge decisions and resource utilisation. Increasing number of our urinary drugs of abuse (DOA) screens had a turnaround time (TAT) of up to 33 days after the discharge of the patient.
  
  
  METHODS
  Following an audit and a consultation period with clinicians using the service, a policy change was implemented to reduce the use of gas chromatography mass spectroscopy (GCMS): all requests would have a standard immunoassay (IA) test panel undertaken unless specifically they requested GCMS (including medico-legal) analysis.
  
  
  RESULTS
  Almost all of the clinicians interviewed had no understanding of the DOA screening or the difference in the information generated between a confirmatory GCMS urine toxicology screen and IA DOA panel. It appeared none of the patients surveyed in the audit would have had a different clinical decision made if a GCMS had not been undertaken. Post change audit showed only 4.3% of drug requests for IA also received a confirmatory GCMS testing. The estimated saving post change implementation was $127,000 (AU $) in test costs alone over a two year period. The TAT of GCMS results was reduced to 3-4 days.
  
  
  CONCLUSIONS
  A laboratory-led behavioural change in test requesting is possible and sustainable provided the reason is clinically sound and accompanied by consultation and availability of advice by phone when requested on test requesting or interpretation.
authors.affiliation: Chemical Pathology, Princess Alexandra Hospital, Queensland, Australia. goce_dimeski@health.qld.gov.au
authors.forename: Goce
authors.initials: G
authors.lastname: Dimeski
authors.forename: Breeann
authors.initials: B
authors.lastname: Silvester
authors.forename: Jacobus
authors.initials: J
authors.lastname: Ungerer
authors.forename: Leslie
authors.initials: L
authors.lastname: Johnson
authors.forename: Jennifer H
authors.initials: JH
authors.lastname: Martin
mesh_terms: D003362:Cost-Benefit Analysis; D008401:Gas Chromatography-Mass Spectrometry / Q000191:economics* / Q000379:methods*; D006801:Humans; D007902:Length of Stay / Q000191:economics / Q000331:legislation & jurisprudence; D016134:Organizational Policy; D010351:Patient Discharge / Q000191:economics / Q000331:legislation & jurisprudence; D011050:Policy Making; D015813:Substance Abuse Detection / Q000191:economics* / Q000379:methods*; D013997:Time Factors; D016482:Urinalysis / Q000191:economics* / Q000379:methods*